152 related articles for article (PubMed ID: 21305610)
1. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective.
Souza RP; Meltzer HY; Lieberman JA; Voineskos AN; Remington G; Kennedy JL
Hum Psychopharmacol; 2011 Jan; 26(1):21-7. PubMed ID: 21305610
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
[TBL] [Abstract][Full Text] [Related]
3. Serum prolactin and tardive dyskinesia.
Glazer WM; Moore DC; Bowers MD; Brown WA
Am J Psychiatry; 1981 Nov; 138(11):1493-6. PubMed ID: 6117204
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
Tripodianakis J; Markianos M; Garelis E
Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
[TBL] [Abstract][Full Text] [Related]
5. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.
Park SW; Lee JG; Kong BG; Lee SJ; Lee CH; Kim JI; Kim YH
Psychiatry Clin Neurosci; 2009 Aug; 63(4):433-9. PubMed ID: 19457211
[TBL] [Abstract][Full Text] [Related]
6. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics.
Csernansky JG; Prosser E; Kaplan J; Mahler E; Berger PA; Hollister LE
Biol Psychiatry; 1986 Jun; 21(7):632-42. PubMed ID: 2871874
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility.
Ivanova SA; Toshchakova VA; Filipenko ML; Fedorenko OY; Boyarko EG; Boiko AS; Semke AV; Bokhan NA; Aftanas LI; Loonen AJ
World J Biol Psychiatry; 2015 Apr; 16(3):200-5. PubMed ID: 25602162
[TBL] [Abstract][Full Text] [Related]
9. Does clozapine cause tardive dyskinesia?
Kane JM; Woerner MG; Pollack S; Safferman AZ; Lieberman JA
J Clin Psychiatry; 1993 Sep; 54(9):327-30. PubMed ID: 8104929
[TBL] [Abstract][Full Text] [Related]
10. Clozapine efficacy in tardive dyskinesia in schizophrenic patients.
Bassitt DP; Louzã Neto MR
Eur Arch Psychiatry Clin Neurosci; 1998; 248(4):209-11. PubMed ID: 9810484
[TBL] [Abstract][Full Text] [Related]
11. Treatment of clozapine-associated tardive dyskinesia.
Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744
[No Abstract] [Full Text] [Related]
12. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Emsley R; Turner HJ; Schronen J; Botha K; Smit R; Oosthuizen PP
J Clin Psychiatry; 2004 May; 65(5):696-701. PubMed ID: 15163258
[TBL] [Abstract][Full Text] [Related]
13. Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Bergman H; Soares-Weiser K
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000204. PubMed ID: 29341071
[TBL] [Abstract][Full Text] [Related]
14. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
[TBL] [Abstract][Full Text] [Related]
15. The treatment of tardive dyskinesia and tardive dystonia.
Simpson GM
J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland.
Nyante SJ; Faupel-Badger JM; Sherman ME; Pfeiffer RM; Gaudet MM; Falk RT; Andaya AA; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Chanock S; Garcia-Closas M; Figueroa JD
Breast Cancer Res; 2011 Apr; 13(2):R42. PubMed ID: 21470416
[TBL] [Abstract][Full Text] [Related]
17. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances.
Tenback DE; van Harten PN; Slooff CJ; van Os J;
Neuropsychopharmacology; 2006 Aug; 31(8):1832-7. PubMed ID: 16482082
[TBL] [Abstract][Full Text] [Related]
18. Tardive dyskinesia rates with atypical antipsychotics in older adults.
Jeste DV
J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
[TBL] [Abstract][Full Text] [Related]
19. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis.
Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE
Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311
[No Abstract] [Full Text] [Related]
20. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
